Oluchi Chilaka
Psychiatric/Mental Health · Denville, NJNPI 1336651520
Payments from drug & device makers
Across 876 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$5K
- AbbVie$4K
- Alkermes, Inc.$3K
- Neurocrine Biosciences, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $4K from 15 others
What the payments were for
- Food & beverage$21,96098%
- Education$3812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 168 | $4,574 |
| AbbVie | 142 | $4,098 |
| Alkermes, Inc. | 116 | $3,439 |
| Neurocrine Biosciences, Inc. | 85 | $2,724 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 84 | $1,828 |
| Otsuka America Pharmaceutical, Inc. | 97 | $1,825 |
| E.r. Squibb & Sons, L.L.C. | 27 | $726 |
| Vanda Pharmaceuticals Inc. | 30 | $700 |
| Supernus Pharmaceuticals, Inc. | 26 | $521 |
| Lundbeck LLC | 25 | $380 |
| Axsome Therapeutics, Inc. | 20 | $354 |
| Corium, LLC | 18 | $330 |
| Johnson & Johnson | 6 | $254 |
| Sunovion Pharmaceuticals Inc. | 11 | $162 |
| Janssen Scientific Affairs, LLC | 1 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Bausch Health US, LLC | 5 | $77 |
| Almatica Pharma LLC | 4 | $56 |
| Validus Pharmaceuticals LLC | 2 | $33 |
| Indivior Inc. | 2 | $33 |
| Luye Pharma (USA) Ltd. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,418
- LYBALVI$2,182
- VRAYLAR$1,808
- INGREZZA$1,578
- ARISTADA INITIO$667
- UZEDY$619
- CAPLYTA$601
- AUSTEDO$474
- Austedo XR$458
- COBENFY$244
- Fanapt$243
- REXULTI$241
- VIVITROL$229
- QELBREE$125
- Azstarys$114
- SPRAVATO$106
- ABILIFY MAINTENA$104
- ABILIFY ASIMTUFII$104
How this compares
$22,341 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 33 | $233,500 |
| Invega SustennaPaliperidone Palmitate | 68 | $206,887 |
| Abilify MaintenaAripiprazole | 61 | $159,829 |
| Abilify AsimtufiiAripiprazole | 22 | $121,864 |
| VraylarCariprazine Hcl | 56 | $84,009 |
| UzedyRisperidone | 12 | $40,440 |
| VivitrolNaltrexone Microspheres | 13 | $20,259 |
| Clozapine | 108 | $12,270 |
| Aripiprazole | 131 | $11,591 |
| Lurasidone Hcl | 25 | $9,976 |
| Divalproex Sodium ErDivalproex Sodium | 149 | $7,830 |
| Olanzapine | 59 | $6,408 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 89 | $4,222 |
| Oxcarbazepine | 70 | $4,154 |
| Haloperidol | 118 | $3,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $1,825 | $281,69383 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $4,574 | $273,94045 claims |
| Johnson & JohnsonInvega Sustenna | $254 | $206,88768 claims |
| AbbVieVraylar | $4,098 | $84,00956 claims |
| Alkermes, Inc.Vivitrol | $3,439 | $20,25913 claims |
| Almatica Pharma LLCSertraline Hcl | $56 | $965194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Denville
- Kathleen KilcoyneDenville$7K
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.